在患有高级固体瘤的患者中,对选择性VEGFR-2血管生成抑制剂rivoceranib进行了1/2a期研究
Yoon-Koo Kang1, Min-Hee Ryu1, Yong Sang Hong1
1Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Cancer research and treatment
|January 25, 2024
概括
利沃赛拉尼布是一种口服的氨酸激酶抑制剂,在患有晚期固体瘤的患者中表现出足够的疗效和可管理的安全性. 推的第二阶段剂量是每天一次685毫克.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 利沃赛拉尼布是一种口服的氨酸激酶抑制剂,向血管内皮生长因子受体2.
- 先进的固体瘤往往对传统疗法表现出耐药性,需要新的治疗方法.
研究的目的:
- 评估rivoceranib在患有晚期固体瘤的患者中的安全性,药理动力学和抗瘤活性.
- 为了确定rivoceranib在这个患者群体中推的2期剂量.
主要方法:
- 进行了一项开放标签,单臂,剂量升级的1/2a期多中心试验.
- 晚期固体瘤对常规治疗不耐药的患者在第1部分接受了升级剂量的rivoceranib (81毫克至685毫克),其次是第2部分的685毫克,以及胃癌患者的第3部分的805毫克.
主要成果:
- 总共招募了61名患者.
- 常见的3级以上的不良事件包括高血压 (32.7%). 在第一部分和第二部分,客观响应率 (ORR) 为15.2%.
- 在第三部分,ORR为33%,在两名患者中观察到剂量限制性毒性.
结论:
- 推的第2期rivoceranib剂量是685毫克每天一次.
- 利沃赛拉尼布在患有晚期固体瘤的患者中显示出足够的疗效和可管理的安全性.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Drug Administration and Therapy Phases: Overview
468
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
468
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K


